Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @KathyGiusti
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @KathyGiusti
-
Thought provoking
@nytimes article from@hemprope on her father's end of life story.https://bddy.me/31erw29Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Love this piece on
@Jenn_RTR! Great read!#FridayReads@moiraforbeshttps://twitter.com/moiraforbes/status/1223259860294340609 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Thrilled to see
#NexImmune, our first Myeloma Investment Fund partner, make this list!http://bit.ly/2tU3v46Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
This simple tool addresses cancer survival rates - one of the most common questions newly diagnosed patients have.https://bddy.me/2Gh3rhc
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Happy Birthday
@Mariska! Heartfelt quotes from@theMMRF Honorary Board Member on her special day!https://www.huffpost.com/entry/mariska-hargitay-motherhood-quotes_l_5e272acbc5b673621f7cba24 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Vivian Lee and Jessica Mega walk us through the innovative initiatives at
#Verily Life Sciences. Proud to be part of their advisory board!https://bddy.me/3aA6qzmHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Such an inspiring organization focused on empowering students to be the next generation of cancer fighters. Love
@dbaum12 and@hightwr73's story. https://bddy.me/2v5c1NN@SupportSmac#peaceoutcancerHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Fantastic news for patients! The
@US_FDA grants priority review of belantamab mafodotin for patients with relapsed or refractory multiple myeloma. This means myeloma patients may soon have another treatment option.https://www.gsk.com/en-gb/media/press-releases/us-food-and-drug-administration-fda-grants-priority-review-of-belantamab-mafodotin-for-patients-with-relapsed-or-refractory-multiple-myeloma/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Insightful piece in
@PharmaVOICE on who drives#innovation in#pharma. Big & small pharma both play important roles, this explores the symbiotic relationship between the two.https://bddy.me/2G3O2knHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Love this piece on the importance of good strategy in
@HarvardBiz. https://bddy.me/2u6rZXz#FridayReadsHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Great interview in
@HBSWK! Can't wait to read@klakhani &@marcoiansiti's new book on#AI & Business Strategy. https://bddy.me/2tqhrm0#WorkingKnowledgeHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Exciting to see a new drug for pancreatic cancer which has such a high mortality rate and unmet need. https://bddy.me/3agu9o8
@PanCAN@JulieFleshmanHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Applaud these
#biotech,#pharma &#healthcare leaders for their commitment to recognizing patient needs. More in@statnews https://bddy.me/38gFqmJ#patientfirstHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Impressed to see
@23andme translating patient data into new treatments. https://www.bloomberg.com/news/articles/2020-01-09/23andme-licenses-drug-compound-to-spanish-drugmaker-almirall …#genomics#ImmunotherapyHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Thrilled to hear that
@BlueprintMeds had their first cancer drug approved by the@US_FDA. One of my favorite recent case studies at@HBSExecEd.https://www.biopharmadive.com/news/blueprint-Ayvakit-FDA-approval-GIST-cancer/570223/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
So proud of what we accomplished at
@theMMRF in 2019. Excited to take it even further in 2020!https://twitter.com/theMMRF/status/1214673379543916551 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Fantastic News! Cancer deaths declined for the 26th year in a row in the US. We saw the largest-ever single-year drop in cancer deaths ever!
#curecancer@LUNGevityhttps://www.cnn.com/2020/01/08/health/cancer-death-rate-largest-decline-year-us-study/index.html …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Love this interview with
@theMMRF honorary board member@SugarRayLeonard!@HarvardBiz does an amazing job capturing his story.http://ow.ly/MQB750xLVcTHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The
@NIHDirector's first blog of 2020 covers three significant breakthroughs of 2019.http://ow.ly/e3Wm50xLUUcHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
As 2019 comes to an end, I'm incredibly grateful for an amazing year full of family, friends and a lot of hard, rewarding work. In 2020, I know we will keep up our great momentum as we strive towards cures.pic.twitter.com/UqPSjbawWL
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.